A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

NCT04161495 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
159
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bioverativ, a Sanofi company